Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.26
RHHVF's Cash to Debt is ranked lower than
91% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. RHHVF: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
RHHVF' s Cash to Debt Range Over the Past 10 Years
Min: 0.26  Med: 0.64 Max: N/A
Current: 0.26
Equity to Asset 0.25
RHHVF's Equity to Asset is ranked lower than
85% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. RHHVF: 0.25 )
Ranked among companies with meaningful Equity to Asset only.
RHHVF' s Equity to Asset Range Over the Past 10 Years
Min: 0.09  Med: 0.25 Max: 0.59
Current: 0.25
0.09
0.59
Interest Coverage 18.16
RHHVF's Interest Coverage is ranked lower than
82% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RHHVF: 18.16 )
Ranked among companies with meaningful Interest Coverage only.
RHHVF' s Interest Coverage Range Over the Past 10 Years
Min: 5.94  Med: 12.43 Max: N/A
Current: 18.16
F-Score: 5
Z-Score: 3.59
M-Score: -2.86
WACC vs ROIC
6.27%
28.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 27.49
RHHVF's Operating margin (%) is ranked higher than
91% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. RHHVF: 27.49 )
Ranked among companies with meaningful Operating margin (%) only.
RHHVF' s Operating margin (%) Range Over the Past 10 Years
Min: 25.03  Med: 28.74 Max: 33.69
Current: 27.49
25.03
33.69
Net-margin (%) 17.53
RHHVF's Net-margin (%) is ranked higher than
87% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. RHHVF: 17.53 )
Ranked among companies with meaningful Net-margin (%) only.
RHHVF' s Net-margin (%) Range Over the Past 10 Years
Min: 15.87  Med: 18.73 Max: 22.97
Current: 17.53
15.87
22.97
ROE (%) 48.21
RHHVF's ROE (%) is ranked higher than
97% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. RHHVF: 48.21 )
Ranked among companies with meaningful ROE (%) only.
RHHVF' s ROE (%) Range Over the Past 10 Years
Min: 19.94  Med: 45.85 Max: 102.95
Current: 48.21
19.94
102.95
ROA (%) 12.44
RHHVF's ROA (%) is ranked higher than
92% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. RHHVF: 12.44 )
Ranked among companies with meaningful ROA (%) only.
RHHVF' s ROA (%) Range Over the Past 10 Years
Min: 10.33  Med: 12.78 Max: 17.58
Current: 12.44
10.33
17.58
ROC (Joel Greenblatt) (%) 62.92
RHHVF's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. RHHVF: 62.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RHHVF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 52.39  Med: 64.09 Max: 84.52
Current: 62.92
52.39
84.52
Revenue Growth (3Y)(%) 3.20
RHHVF's Revenue Growth (3Y)(%) is ranked lower than
52% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. RHHVF: 3.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RHHVF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -78  Med: 3.2 Max: 390.8
Current: 3.2
-78
390.8
EBITDA Growth (3Y)(%) -0.40
RHHVF's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. RHHVF: -0.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RHHVF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -88.5  Med: 3.6 Max: 268.9
Current: -0.4
-88.5
268.9
EPS Growth (3Y)(%) -2.30
RHHVF's EPS Growth (3Y)(%) is ranked higher than
51% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. RHHVF: -2.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RHHVF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.2  Med: 6.9 Max: 340.9
Current: -2.3
-3.2
340.9
GuruFocus has detected 3 Warning Signs with Roche Holding AG $RHHVF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RHHVF's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-07-21)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with RHHVF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AMGN, NAS:CELG, NAS:GILD, OTCPK:NONOF, NAS:BIIB, OTCPK:SHPGF, OTCPK:CSLLY, NAS:REGN, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, NAS:BMRN, OTCPK:GIKLY, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:NVZMY, NAS:TSRO, NAS:SGEN, NAS:ALKS » details
Traded in other countries:RHO5.Germany, ROG N.Mexico, RO.Switzerland, 0QOK.UK,
Roche Holding AG is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience.

Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience. It has more than 66 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals and Chugai, whereas Genentech as the former third segment has been integrated into Roche Pharmaceuticals. The Diagnostics Division consists of the following four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Ratios

vs
industry
vs
history
P/E(ttm) 23.37
RHHVF's P/E(ttm) is ranked higher than
59% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. RHHVF: 23.37 )
Ranked among companies with meaningful P/E(ttm) only.
RHHVF' s P/E(ttm) Range Over the Past 10 Years
Min: 13.05  Med: 19.61 Max: 29.42
Current: 23.37
13.05
29.42
Forward P/E 14.77
RHHVF's Forward P/E is ranked higher than
69% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. RHHVF: 14.77 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.37
RHHVF's PE(NRI) is ranked higher than
59% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. RHHVF: 23.37 )
Ranked among companies with meaningful PE(NRI) only.
RHHVF' s PE(NRI) Range Over the Past 10 Years
Min: 13.05  Med: 19.61 Max: 29.2
Current: 23.37
13.05
29.2
Price/Owner Earnings (ttm) 16.92
RHHVF's Price/Owner Earnings (ttm) is ranked higher than
67% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. RHHVF: 16.92 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RHHVF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.58  Med: 15.16 Max: 23.23
Current: 16.92
9.58
23.23
P/B 11.37
RHHVF's P/B is ranked lower than
87% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. RHHVF: 11.37 )
Ranked among companies with meaningful P/B only.
RHHVF' s P/B Range Over the Past 10 Years
Min: 2.64  Med: 11.37 Max: 22.21
Current: 11.37
2.64
22.21
P/S 4.21
RHHVF's P/S is ranked higher than
74% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. RHHVF: 4.21 )
Ranked among companies with meaningful P/S only.
RHHVF' s P/S Range Over the Past 10 Years
Min: 2.38  Med: 3.89 Max: 5.46
Current: 4.21
2.38
5.46
PFCF 19.06
RHHVF's PFCF is ranked higher than
56% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. RHHVF: 19.06 )
Ranked among companies with meaningful PFCF only.
RHHVF' s PFCF Range Over the Past 10 Years
Min: 8.6  Med: 17.1 Max: 37.16
Current: 19.06
8.6
37.16
POCF 13.92
RHHVF's POCF is ranked higher than
68% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. RHHVF: 13.92 )
Ranked among companies with meaningful POCF only.
RHHVF' s POCF Range Over the Past 10 Years
Min: 6.98  Med: 13.45 Max: 22.22
Current: 13.92
6.98
22.22
EV-to-EBIT 17.96
RHHVF's EV-to-EBIT is ranked higher than
52% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. RHHVF: 17.96 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHVF' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.6  Med: 14 Max: 19.8
Current: 17.96
7.6
19.8
EV-to-EBITDA 13.99
RHHVF's EV-to-EBITDA is ranked higher than
56% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. RHHVF: 13.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
RHHVF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 11.8 Max: 15.7
Current: 13.99
6.4
15.7
PEG 20.00
RHHVF's PEG is ranked lower than
95% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. RHHVF: 20.00 )
Ranked among companies with meaningful PEG only.
RHHVF' s PEG Range Over the Past 10 Years
Min: 0.24  Med: 3.1 Max: 23.21
Current: 20
0.24
23.21
Shiller P/E 21.83
RHHVF's Shiller P/E is ranked higher than
82% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. RHHVF: 21.83 )
Ranked among companies with meaningful Shiller P/E only.
RHHVF' s Shiller P/E Range Over the Past 10 Years
Min: 18.29  Med: 23.55 Max: 34.49
Current: 21.83
18.29
34.49
Current Ratio 1.09
RHHVF's Current Ratio is ranked lower than
87% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. RHHVF: 1.09 )
Ranked among companies with meaningful Current Ratio only.
RHHVF' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 1.85 Max: 3.75
Current: 1.09
1.09
3.75
Quick Ratio 0.75
RHHVF's Quick Ratio is ranked lower than
89% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. RHHVF: 0.75 )
Ranked among companies with meaningful Quick Ratio only.
RHHVF' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.5 Max: 3.22
Current: 0.75
0.75
3.22
Days Inventory 179.02
RHHVF's Days Inventory is ranked lower than
66% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. RHHVF: 179.02 )
Ranked among companies with meaningful Days Inventory only.
RHHVF' s Days Inventory Range Over the Past 10 Years
Min: 143.33  Med: 157.18 Max: 186.16
Current: 179.02
143.33
186.16
Days Sales Outstanding 64.10
RHHVF's Days Sales Outstanding is ranked lower than
52% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. RHHVF: 64.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHVF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.32  Med: 74.15 Max: 84.09
Current: 64.1
60.32
84.09
Days Payable 57.68
RHHVF's Days Payable is ranked higher than
50% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. RHHVF: 57.68 )
Ranked among companies with meaningful Days Payable only.
RHHVF' s Days Payable Range Over the Past 10 Years
Min: 49.43  Med: 59.56 Max: 78.64
Current: 57.68
49.43
78.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.33
RHHVF's Dividend Yield is ranked higher than
83% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. RHHVF: 3.33 )
Ranked among companies with meaningful Dividend Yield only.
RHHVF' s Dividend Yield Range Over the Past 10 Years
Min: 1.06  Med: 2.94 Max: 4.55
Current: 3.33
1.06
4.55
Dividend Payout 0.77
RHHVF's Dividend Payout is ranked lower than
87% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. RHHVF: 0.77 )
Ranked among companies with meaningful Dividend Payout only.
RHHVF' s Dividend Payout Range Over the Past 10 Years
Min: 0.31  Med: 0.58 Max: 0.78
Current: 0.77
0.31
0.78
Dividend Growth (3y) 5.60
RHHVF's Dividend Growth (3y) is ranked lower than
55% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. RHHVF: 5.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
RHHVF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 10.8 Max: 27.3
Current: 5.6
0
27.3
Forward Dividend Yield 3.39
RHHVF's Forward Dividend Yield is ranked higher than
90% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.38 vs. RHHVF: 3.39 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.44
RHHVF's Yield on cost (5-Year) is ranked higher than
79% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. RHHVF: 4.44 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RHHVF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.41  Med: 3.92 Max: 6.06
Current: 4.44
1.41
6.06
3-Year Average Share Buyback Ratio -0.10
RHHVF's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. RHHVF: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RHHVF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -364.1  Med: 0 Max: 78.5
Current: -0.1
-364.1
78.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Earnings Based) 2.18
RHHVF's Price/DCF (Earnings Based) is ranked lower than
81% of the 21 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. RHHVF: 2.18 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Earnings Yield (Greenblatt) (%) 5.60
RHHVF's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. RHHVF: 5.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RHHVF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5  Med: 7.2 Max: 13.1
Current: 5.6
5
13.1
Forward Rate of Return (Yacktman) (%) 6.78
RHHVF's Forward Rate of Return (Yacktman) (%) is ranked lower than
63% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. RHHVF: 6.78 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RHHVF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4.5  Med: 8.9 Max: 62.3
Current: 6.78
4.5
62.3

More Statistics

Revenue (TTM) (Mil) $52,759
EPS (TTM) $ 10.76
Beta0.63
Short Percentage of Float0.00%
52-Week Range $216.45 - 270.00
Shares Outstanding (Mil)852.21

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 50,729 54,553 59,879
EPS ($) 15.01 16.22 17.32
EPS w/o NRI ($) 15.01 16.22 17.32
EPS Growth Rate
(3Y to 5Y Estimate)
8.30%
Dividends Per Share ($) 8.11 8.40 9.03
» More Articles for RHHVF

Headlines

Articles On GuruFocus.com
A Would-Be Dividend Aristocrat With a 3.5% Dividend Yield Jan 24 2017 
Blake Insomnia CEO Dreams of Improving Sleep Jan 04 2017 
Roche's Leukemia Drug Approved for Next Step in Europe Dec 11 2016 
Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee Oct 14 2016 
Mairs and Power Buys Walt Disney, Exits Baxalta Sep 27 2016 
Is Bristol-Myers Squibb Presenting an Opportunity? Sep 08 2016 
Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
Innovative Diagnostic and Therapeutic Products Seen at Roche Aug 22 2016 
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 

More From Other Websites
Roche says Phase II trial supports twin treatment for kidney cancer Feb 18 2017
These Are The First Immune-System Cancer Drugs OK'd By FDA Feb 17 2017
AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink Feb 17 2017
Roche Urges New Plan as Swiss Tax Vote Seen Slowing Investment Feb 13 2017
Roche Fights Roche for $9 Billion Drug Business Feb 13 2017
Roche Holding AG :RHHVF-US: Earnings Analysis: For the six months ended December 31, 2016 : February... Feb 06 2017
Roche Holding AG :RHHVF-US: Earnings Analysis: 2016 By the Numbers : February 3, 2017 Feb 03 2017
Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales Feb 02 2017
Roche CEO Shrugs Off Trump's Drug Stance; 2016 Sales Narrowly Miss Feb 01 2017
[$$] Roche Unfazed by Trump's Drug-Price Comments Feb 01 2017
Roche Shares Gain; CEO 'Fully Dedicated' to Key U.S. Market Feb 01 2017
Competition stalls Roche margin growth; drugmaker commits to diabetes unit Feb 01 2017
Roche Posts Solid 2016 Profit, 2017 Outlook; Dividend Falls Short Feb 01 2017
Roche Sees Profit Growth Hiccup as Old Drug Guard Gets Replaced Feb 01 2017
Roche said to consider options for Diabetes unit- Bloomberg Jan 31 2017
Roche Considers Options for Diabetes Unit Including Sale Jan 31 2017
I-O Players Incyte, Roche Squeeze Array's Melanoma Market: Leerink Jan 30 2017
Will Merck Let Incyte Go After AstraZeneca, Bristol, Roche Team-Ups Too? Jan 27 2017
Roche (RHHBY) Arthritis Drug Actemra sBLA Accepted by FDA Jan 25 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)